FDA Approves Marketing of Lab Test for Acute Kidney Injury Risk

The NephroCheck test can determine whether certain critically ill, hospitalized patients are at risk of developing moderate to severe acute kidney injury in the 12 hours following the administration of the test.

The U.S. Food and Drug Administration has approved for marketing the NephroCheck test, a laboratory test that can determine whether certain critically ill, hospitalized patients are at risk of developing moderate to severe acute kidney injury in the 12 hours following the administration of the test. "Early knowledge that a patient is likely to develop AKI may prompt closer patient monitoring and help prevent permanent kidney damage or death," according to the agency's Sept. 5 news release.

"AKI is a sudden decline in kidney function, often without early signs or symptoms, following an injury to the kidney caused by a co-existing disease, infection, or other condition. AKI can cause fluid to build up in the body, chest pain, muscle weakness, and permanent kidney damage or chronic kidney disease (the gradual loss of kidney function). Critically ill patients are the most at risk for AKI, particularly patients who meet certain factors such as advanced age, diabetes and high blood pressure," the release states. "Current laboratory tests can only assess whether a patient may already have AKI; often, the patient has progressed to moderate to severe AKI before the test results confirm the clinical diagnosis. NephroCheck detects the presence of insulin-like growth-factor binding protein 7 (IGFBP7) and tissue inhibitor of metalloproteinases (TIMP-2) in the urine, which are associated with acute kidney injury. Within 20 minutes, the test provides a score based on the amount of the proteins present that correlates to the patient's risk of developing AKI within 12 hours of the test being performed. No other tests currently on the market are FDA-approved or cleared to assess the risk of developing AKI in at-risk patients."

"Early assessment and timely treatment for AKI can help prevent kidney damage and potential associated complications," said Alberto Gutierrez, director of the Office of In Vitro Diagnostics and Radiological Health at FDA's Center for Devices and Radiological Health. "The NephroCheck provides health care providers with a quick, validated method of assessing a patient’s AKI risk status which may inform patient management decisions."

The NephroCheck Test System is manufactured by Astute Medical based in San Diego, Calif.

comments powered by Disqus

OH&S Digital Edition

  • OHS Magazine Digital Edition - October 2019

    October 2019

    Featuring:

    • WINTER HAZARDS
      Preparing for Old Man Winter's Arrival
    • CONSTRUCTION
      Staying Safe in the Trenches
    • INDUSTRIAL HYGIENE
      Setting a Higher Standard: The Limitations of Regulatory Limits
    • ELECTRICAL SAFETY
      Five Important Things to Know About Arc Flash PPE Programs
    View This Issue